A Call to Action for Healthcare Professionals For registered dietitians and diabetes care and education specialists, this moment is a call to step forward
Patients should seek immediate medical attention for and discontinue semaglutide if they experience: Severe, persistent abdominal pain (possible pancreatitis) Signs of thyroid tumors (neck mass, difficulty swallowing, persistent hoarseness) Symptoms of gallbladder disease (right upper quadrant pain, especially after meals) Severe hypoglycemia (when combined with insulin or sulfonylureas) Signs of kidney problems (decreased urination, swelling, fatigue) Suicidal thoughts or behaviors (particularly with Wegovy) Vision changes (especially in patients with diabetes and pre-existing retinopathy) Regular follow-up with healthcare providers is essential to monitor treatment response, adjust dosing, manage side effects, and assess cardiovascular risk factors including blood pressure, glucose control, and lipid profiles
However, carefully selected tests may provide information about inflammation, atherogenic cholesterol particles, metabolic risk, lipid oxidation, and antioxidant status
Women with: BMI within prescribing criteria Documented insulin resistance Repeated unsuccessful lifestyle attempts No pregnancy plans in the immediate future Eligibility guidance is further explained in who is eligible for weight loss injections in the UK
For lean individuals, the skin pinch is not optional
